Anti-Müllerian Hormone is produced by granulosa cells in developing ovarian follicles in women and by Sertoli cells in the testes in men. In women, AMH reflects ovarian reserve, the remaining supply of eggs available for ovulation. Unlike FSH, AMH stays relatively stable across the menstrual cycle, making it a convenient single-timepoint measure.
AMH is the clearest single-lab window into reproductive biological age. Levels decline predictably with age (roughly 10-15% per year after 30), so AMH tracks the fertility window more tightly than FSH or estradiol. Very low AMH suggests diminished ovarian reserve; very high AMH is characteristic of PCOS, where antral follicle count is elevated but ovulation is disrupted. AMH doesn't capture egg quality, so it's not a complete fertility predictor, but for tracking reserve and timing family-planning decisions, it's the best marker available.
Optimal AMH: 1-4 ng/mL.
Typically re-tested every 26 weeks.
AMH is measured from a standard blood draw and usually reported in ng/mL. A typical lab reference range sits around 0.5 to 6.5 ng/mL, and FitScript's optimal range is 1 to 4 ng/mL in women and 1 to 5 ng/mL in men.
AMH is a glycoprotein hormone produced by the granulosa cells of small, growing ovarian follicles in women and by the Sertoli cells of the testes in men.
The hormone was first described for its role before birth. In male fetal development, AMH released by the testes drives regression of the Müllerian ducts, the tissue that would otherwise form the uterus and upper vagina, and it is also involved in the process of testicular descent[1]. In males, AMH is high through childhood and falls sharply at puberty as intratesticular testosterone rises, which is why an adult male value is normally low.
In women, AMH production comes almost entirely from preantral and small antral follicles, the pool of follicles that have begun to grow but have not yet been selected for ovulation[2]. Because the size of that growing pool tracks the size of the remaining resting pool, a blood level works as an indirect estimate of ovarian reserve. AMH also appears to act as a brake inside the ovary, restraining recruitment of resting follicles and reducing follicular sensitivity to FSH, so the reserve is not spent too quickly[2].
Two practical features follow from that biology. First, AMH varies less across the menstrual cycle than FSH or estradiol, so the timing of the draw is less restrictive than for most reproductive hormones[3]. Second, the value is shaped by both inherited and environmental factors, which is one reason two people of the same age can sit far apart on the same assay[4].
AMH matters because it is one of the few blood markers that gives a quantitative read on ovarian reserve, and ovarian reserve sits upstream of reproductive timing and of the hormonal environment that follows menopause.
In reproductive medicine, AMH is used alongside antral follicle count to assess ovarian function and to anticipate how the ovaries are likely to respond to stimulation during assisted reproduction[3]. Research suggests it correlates reasonably well with the number of oocytes retrieved, while performing much less well as a predictor of natural conception in a given cycle or of egg quality[5]. That distinction is the single most misunderstood thing about this marker. A number describes quantity, not the chance of a pregnancy.
The second use is timing. A systematic review of AMH for the diagnosis and prediction of menopause found that AMH carries real information about the approach of the final menstrual period, though its precision for an individual woman remains limited rather than exact[6]. More recent work reviews the same question across ovarian reserve, primary ovarian insufficiency and menopause prediction, and reaches a similar place, useful signal with meaningful uncertainty around any single estimate[7].
There is also emerging interest in AMH outside the gonads. Studies indicate that AMH receptors are present on GnRH neurons and pituitary cells, suggesting the hormone may have a role in hypothalamic-pituitary regulation rather than acting only locally in the ovary[8]. That work is early, and no clinical decision rests on it yet.
For a reader tracking long-term health, the value of AMH is context. It helps frame family-planning decisions years before they become urgent, and it adds useful context when cycles start changing.
A normal AMH is any value inside your laboratory's reference range for your age and sex, and an optimal value is a narrower band used as an optimization target rather than a diagnostic threshold.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| AMH, women | 0.5 to 6.5 ng/mL | 1 to 4 ng/mL |
| AMH, men | 0.5 to 8 ng/mL | 1 to 5 ng/mL |
| AMH, adults, general | 0.5 to 6.5 ng/mL | 1 to 4 ng/mL |
A nationwide Korean study (KNHANES 2013 to 2016) measured AMH with the Roche Elecsys assay in 1,450 healthy women aged 19 to 54.[13] The range dropped sharply with age, especially after 40.[13]
| Sex | Age | Reference range (pmol/L) |
|---|---|---|
| Women | 19 to 24 | 7.93 to 81.21 |
| Women | 25 to 29 | 5.64 to 72.64 |
| Women | 30 to 34 | 1.14 to 78.43 |
| Women | 35 to 39 | 1.36 to 48.14 |
| Women | 40 to 44 | 0.07 to 35.93 |
| Women | 45 to 49 | 0.07 to 17.79 |
| Women | 50 to 54 | 0.07 to 3.86 |
Ranges are the 2.5th to 97.5th percentiles for seven 5-year age groups, reported in pmol/L (the paper's unit, not converted to ng/mL). Your own lab's printed range is the one to read your result against, since AMH values differ between assays.
These are typical lab reference ranges, and they vary by laboratory, age and sex. The optimal ranges shown are FitScript's optimization targets, not diagnostic cut-offs, and no single value inside or outside them identifies a condition on its own.
Two details change how a number should be read. AMH declines with age in women across adult life, so an age-referenced range from the reporting laboratory is more informative than a single adult band. And assays differ. Values from different platforms are not always interchangeable, which is why a repeat test is best run at the same laboratory where possible[3]. If your report lists age-specific ranges, use those rather than a generic adult range.
An AMH above the reference range usually reflects a large number of small antral follicles, and in women the most common clinical association is polycystic ovary syndrome or polycystic ovarian morphology.
What people report. A high value itself produces no symptoms. What people notice is the pattern that can accompany it, including irregular or infrequent periods, cycles that are hard to predict, acne, unwanted hair growth, and difficulty conceiving because ovulation is inconsistent. Many people with a high AMH report nothing at all and simply have a generous follicle pool.
Common causes. In people with polycystic ovary syndrome, AMH is frequently elevated, and research suggests the excess comes from a larger pool of small follicles and from increased production per follicle[9]. A systematic review and meta-analysis examined AMH as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology and found useful but imperfect discrimination, with thresholds that shift across assays and populations[10]. Earlier work on AMH and polycystic ovary syndrome reaches a similar conclusion, that the hormone reflects the follicular disturbance rather than defining it[11]. A high value may also appear in younger women simply because reserve is higher earlier in life. Rarely, granulosa cell tumours raise AMH, which is one reason a markedly high value is worth discussing with a clinician rather than filed away.
Longer-term relevance. A high AMH is not harmful in itself. Its significance comes from what it may point toward. Polycystic ovary syndrome is associated with insulin resistance and with metabolic and cardiovascular risk factors over time, so when a high AMH sits beside irregular cycles or signs of androgen excess, metabolic markers are usually worth reviewing in the same visit. Studies of AMH and ovarian dysfunction describe the hormone as a window on how follicle development is being regulated[12]. A high result also predicts stronger ovarian response to stimulation, which matters for anyone considering assisted reproduction and is something a fertility specialist accounts for directly.
A low AMH suggests a smaller pool of growing follicles, which is most often a reflection of age, though it can also follow medical exposures or reflect reduced ovarian function at a younger age than expected.
What people report. Low AMH is usually silent. Where symptoms appear, they tend to involve cycle change, including shorter cycles, more variable cycle length, skipped periods, or the vasomotor symptoms of the menopausal transition. Some people learn about a low value only during fertility assessment, after fewer eggs than expected were retrieved in a stimulation cycle.
Common causes. Age is the dominant one. Beyond that, AMH is reduced after chemotherapy or pelvic radiotherapy, after ovarian surgery such as cyst removal, and in primary ovarian insufficiency, where ovarian function declines early[7]. Genetic variation contributes, and environmental exposures including smoking have been associated with lower values[4]. Hormonal contraception and some hormonal medications are associated with a lower measured value that may not reflect the true underlying reserve[3]. Laboratory and assay differences account for part of the spread as well.
Longer-term relevance. The main implication is timing. Research suggests lower AMH for age is associated with an earlier final menstrual period, although the prediction is a probability spread across years, not a date[6]. For reproductive planning, a lower value is associated with fewer oocytes at retrieval, which is why fertility specialists use it when counselling on options, but it is a poor predictor of whether conception will happen naturally[5]. A suboptimal or low-for-age AMH, particularly before the age of 40 or alongside cycle changes, is worth discussing with a clinician promptly rather than waiting for a repeat in a year.
Several testing, medical and lifestyle factors move an AMH value, and most of them change what the number reads rather than what the ovary holds.
Start with the test itself. Different immunoassays give different absolute values, so comparing a result from one laboratory with one from another can create an apparent change that is only a platform difference[3]. Within a person, AMH fluctuates modestly across the menstrual cycle, less than FSH or estradiol, which is why fasting and strict cycle-day timing are generally not required unless your clinician asks for them. Sample handling and storage can also affect results.
Medications matter. Combined hormonal contraception, GnRH analogues and some other hormonal medicines are associated with lower measured AMH while they are being used, with values commonly rising again after stopping[2]. Any prescription therapy that touches reproductive hormones is evaluated by a licensed provider, who decides whether it is appropriate and how it should be used.
Habits and biology contribute smaller effects. Studies of genetic and environmental influences on AMH point to inherited variation, smoking, body composition and vitamin D status among the factors associated with differences in measured levels, generally as associations rather than demonstrated cause[4]. The honest summary is that no habit reliably restores follicles once they are gone, while not smoking, keeping body composition in a healthy band and correcting documented nutrient deficiencies are reasonable general steps that a clinician can tailor. Detailed strategies for influencing this marker sit outside the scope of this page.
AMH is measured from a venous blood sample and is included in reproductive and hormone-focused lab work rather than a standard metabolic panel.
Within FitScript, a membership built around 150+ biomarkers tested per year, AMH is run as part of hormone testing and is read beside the other reproductive and metabolic markers drawn at the same time, so the number is interpreted in context rather than alone. Atlas, FitScript's AI health advisor, turns that panel into your FitScript, the personalized output written from your own biology, flagging where a result sits relative to typical lab ranges and to optimal targets, and noting which markers to retest and when.
Tracking matters more than any single draw. Because AMH declines with age and varies by assay, a series of values from the same laboratory over time tells you more than one reading ever can. A value that falls faster than expected for age, or one that is markedly high alongside irregular cycles, is the kind of finding that belongs in a conversation with a clinician.
Where results point toward care that requires a prescription, a licensed provider evaluates whether any treatment is appropriate after reviewing your labs, symptoms and history. Nothing on this page, and no automated interpretation, substitutes for that evaluation.
AMH is most informative when it is read with the pituitary and gonadal hormones that describe the same system from different angles.
FSH rises as ovarian reserve falls and gives a complementary, cycle-dependent view of ovarian function, which is why the two are often ordered together. Estradiol is needed to interpret FSH correctly and reflects follicular activity in the current cycle. Progesterone drawn in the luteal phase indicates whether ovulation actually occurred, something AMH cannot show. Testosterone Total and Testosterone Free matter when a high AMH sits beside acne, hair changes or irregular cycles, since androgen status is part of that picture, and in men they explain the normal fall in AMH after puberty. SHBG determines how much testosterone is biologically available and often moves with insulin resistance, which adds metabolic context. These markers are commonly grouped within FitScript Complete for women, which is the practical way to get them from a single draw.
Thyroid markers, prolactin and metabolic markers such as fasting insulin are frequently added when cycles are irregular, because several non-ovarian conditions produce overlapping symptoms.
AMH estimates the size of the growing follicle pool, which makes it a reasonable proxy for ovarian reserve and a useful input for reproductive planning and menopause timing. It says little about egg quality, nothing definitive about the chance of conceiving in a given month, and nothing at all on its own about whether a condition is present. Read it with your age, your cycle history, and the hormones that sit around it, from the same laboratory each time.
This article is educational and is not medical advice. Discuss your AMH result, your full panel and any treatment options with a clinician or licensed provider who can review your history.
A typical lab reference range is around 0.5 to 6.5 ng/mL, and FitScript's optimal range is 1 to 4 ng/mL in women and 1 to 5 ng/mL in men. Ranges vary by laboratory, age and sex, and the optimal band is an optimization target rather than a diagnostic cut-off. Age matters more than the generic adult range, so use the age-referenced range on your own report where one is given.
No. AMH estimates the quantity of small growing follicles, not egg quality or the chance of conceiving in a given month. It tends to correlate with the number of eggs retrieved during assisted reproduction, which is why fertility specialists use it for counselling and planning, but it performs poorly as a predictor of natural conception. Cycle history, age and other hormones all add information a single value cannot.
In women, AMH declines across adult reproductive life as the follicle pool is depleted, and it becomes very low around the menopausal transition. In men, AMH is high in childhood and drops sharply at puberty as testosterone rises, so adult male values are normally low. Because the decline is gradual and individual, an age-referenced range from your reporting laboratory is more useful than a single adult band.
Usually not. AMH varies less across the menstrual cycle than FSH or estradiol, so most laboratories accept a sample on any cycle day and fasting is generally not required. Your clinician may still ask for specific timing when AMH is being drawn alongside cycle-dependent hormones such as FSH, estradiol or luteal progesterone, since those markers do depend on timing.
Combined hormonal contraception and some other hormonal medicines are associated with a lower measured AMH while they are being used, and values commonly rise again after stopping. That means a result taken during contraceptive use may understate the underlying reserve. Mention every hormonal medication you are using when your result is reviewed, and ask a clinician whether a repeat test off medication would be informative.
A high value most often reflects a large number of small antral follicles. In people with polycystic ovary syndrome, AMH is frequently elevated, and it may reflect the follicular disturbance seen in that condition without defining it on its own. Younger age also raises AMH naturally. A markedly high result, especially alongside irregular cycles, is worth discussing with a clinician rather than interpreting alone.
Yes, although it is ordered far less often. AMH is produced by Sertoli cells in the testes and is used mainly in paediatric and andrology settings, for example when assessing testicular tissue in undescended testis or evaluating testicular function. Adult male values are normally low because testosterone suppresses AMH production after puberty. Interpretation in men depends heavily on age and clinical context.
No habit or supplement reliably restores follicles once they are gone, and claims otherwise should be read sceptically. What can change is the measured value, since medications, assay differences and smoking are all associated with shifts in the number. Avoiding smoking, keeping body composition in a healthy band and correcting documented deficiencies are reasonable general steps, and a clinician can advise on what applies to you.